[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK2349310T3 - Polypeptid til behandling eller forebyggelse af adhæsioner - Google Patents

Polypeptid til behandling eller forebyggelse af adhæsioner

Info

Publication number
DK2349310T3
DK2349310T3 DK09830789.5T DK09830789T DK2349310T3 DK 2349310 T3 DK2349310 T3 DK 2349310T3 DK 09830789 T DK09830789 T DK 09830789T DK 2349310 T3 DK2349310 T3 DK 2349310T3
Authority
DK
Denmark
Prior art keywords
polypeptime
adhesions
prevention
treatment
Prior art date
Application number
DK09830789.5T
Other languages
English (en)
Inventor
Alyssa Panitch
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Application granted granted Critical
Publication of DK2349310T3 publication Critical patent/DK2349310T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09830789.5T 2008-10-20 2009-10-20 Polypeptid til behandling eller forebyggelse af adhæsioner DK2349310T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10683408P 2008-10-20 2008-10-20
PCT/US2009/061345 WO2010065206A1 (en) 2008-10-20 2009-10-20 Polypeptide for treating or preventing adhesions

Publications (1)

Publication Number Publication Date
DK2349310T3 true DK2349310T3 (da) 2014-08-11

Family

ID=42108870

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09830789.5T DK2349310T3 (da) 2008-10-20 2009-10-20 Polypeptid til behandling eller forebyggelse af adhæsioner

Country Status (11)

Country Link
US (1) US9034815B2 (da)
EP (1) EP2349310B1 (da)
JP (1) JP5785085B2 (da)
KR (2) KR101884616B1 (da)
CN (1) CN102256613B (da)
AU (1) AU2009322865B2 (da)
BR (1) BRPI0919759A2 (da)
CA (1) CA2741302C (da)
DK (1) DK2349310T3 (da)
ES (1) ES2507496T3 (da)
WO (1) WO2010065206A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
DK2185698T3 (da) 2007-08-07 2015-07-27 Purdue Research Foundation Kinaseinhibitorer og anvendelser deraf
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
CN104302310A (zh) * 2011-04-12 2015-01-21 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病、病状或病程的组合物和方法
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
EP2827841B8 (en) 2012-03-23 2024-10-23 Macro Biologics, Inc. Compositions and uses of antimicrobial materials with tissue-compatible properties
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2016061145A1 (en) * 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
MX2017006372A (es) * 2014-11-17 2017-08-21 Moerae Matrix Inc Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
AU2016205125A1 (en) * 2015-01-08 2017-07-13 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
WO2016145234A2 (en) 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
KR20200018400A (ko) 2017-04-06 2020-02-19 아미크로베, 인코포레이티드. 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도
RU2741247C1 (ru) * 2020-10-13 2021-01-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ профилактики перитонеальных спаек женского таза

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
CA1224992A (en) 1982-10-08 1987-08-04 Robert E. Newell Device for administering medicament to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
IE59026B1 (en) 1985-07-30 1993-12-15 Glaxo Group Ltd Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
EP0672159B1 (en) 1992-04-24 2005-12-28 Sri International Homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
PT733059E (pt) 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
WO2003084481A2 (en) 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
EP1824336A4 (en) * 2004-12-02 2009-10-14 Univ North Carolina INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS
WO2006113667A1 (en) * 2005-04-15 2006-10-26 University Of Arizona Therapeutic peptides for the treatment of metastatic cancer
ES2594281T3 (es) * 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
WO2008109794A2 (en) * 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
DK2185698T3 (da) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinaseinhibitorer og anvendelser deraf
WO2009123759A2 (en) * 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions

Also Published As

Publication number Publication date
KR101884616B1 (ko) 2018-08-06
AU2009322865B2 (en) 2013-07-18
EP2349310B1 (en) 2014-07-23
US20100098760A1 (en) 2010-04-22
KR20170001756A (ko) 2017-01-04
CA2741302A1 (en) 2010-06-10
US9034815B2 (en) 2015-05-19
CA2741302C (en) 2017-02-28
EP2349310A1 (en) 2011-08-03
AU2009322865A1 (en) 2010-06-10
KR20110095867A (ko) 2011-08-25
US20130101671A9 (en) 2013-04-25
CN102256613B (zh) 2014-09-10
JP2012506442A (ja) 2012-03-15
EP2349310A4 (en) 2012-11-21
BRPI0919759A2 (pt) 2017-03-21
ES2507496T3 (es) 2014-10-15
CN102256613A (zh) 2011-11-23
JP5785085B2 (ja) 2015-09-24
WO2010065206A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
DK2349310T3 (da) Polypeptid til behandling eller forebyggelse af adhæsioner
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2207775T3 (da) 4-Benzylamino-1-carboxyacylpiperidinderivater som CETP-inhibitorer, som er anvendelige til behandling af sygdomme som hyperlipidæmi eller arteriosclerose
ZA201008215B (en) Small molecule inhibitors for the treatment or prevention of dengue virus infection
DK2532680T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2240130T3 (da) Indretning til behandling af fedme
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2104674T3 (da) Thiophenanaloger til behandling eller forebyggelse af flavivirus-infektioner
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
DK2532366T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2470191T3 (da) Fremgangsmåder og præparater til forebyggelse eller behandling af oftalmiske tilstande
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2254591T3 (da) Inhibering eller behandling af gastrointestinal biofilm
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2459553T3 (da) Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme
DK2146732T3 (da) Fremgangsmåder til behandling eller forebyggelse af emese ved hjælp af væksthormonsekretagoger
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
DK2768523T3 (da) Fremgangsmåde til behandling eller reduktion af efp
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK3006038T3 (da) Enkeltdoser af oritavancin til behandling eller forebyggelse af en bakterieinfektion